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Summary: Methods employing chromogenic substrates for the photometric determination of prothrombin
time have several advantages over conventional coagulometric methods. We evaluated the analytical qualities
of two recently introduced reagents for the photometric determination of prothrombin time. The assays were
performed on a centrifugal analyser. Both reagents showed good precision, even with sample volumes of 10 μΐ
or 12 μΐ. The stability of the reagents during storage was investigated at 4 °C, 25 °C and 37 °C. The chromogenic
reagent, which contains thromboplastin from human placenta, was compared with a coagulometric method,
which includes ox-brain thromboplastin: coagulation activities calculated from International Normalized
Ratio values showed good correlation and conformity over the whole test range. The other chromogenic
reagent contains thromboplastin from rabbit brain; outside the therapeutic range for oral anticoagulation the
results obtained with this reagent showed poor agreement with those obtained with the coagulometric method.
Both chromogenic reagents were sensitive to reduced concentrations of coagulation factors of the extrinsic
pathway and nearly insensitive to low factor IX concentrations. The results of the photometric test paralleled
those of the clotting method during oral anticoagulation therapy.
Introduction
Since its adoption for monitoring oral coagulation
therapy, the determination of the prothrombin time
introduced by Quick (1, 2) has become the most
frequently performed test in haemostasis laboratories.
In our laboratory 83% of all requests for coagulation
tests require the assay of prothrombin time for ther-
apy control, while in another" 4% the prothrombin
time is used for screening coagulation pathology. The
Thrombotest®, a one-stage coagulometric test for pro-
thrombin time introduced by Owren (3), is widely
used for monitoring anticoagulant treatment, because
it uses a bovine brain thromboplastin with a high
sensitivity to proteins induced by vitamin Κ absence
(PIVKA)', which are produced during treatment with
vitamin Κ antagonists (4, 5). However, the develop-
ment of synthetic peptides, which serve as specific
substrates for particular enzymes of the coagulation
system (6 — 8), has offered attractive possibilities for
the introduction of automated photometric assays of
the prothrombin time (9--16).
We evaluated the analytical qualities of two recently
introduced photometric tests for the measurement of
prothrombin time, which we performed on a centrif-
ugal analyser. Secondly, we compared the results of
both photometric tests with the Thrombotest® in sam-
ples with normal or subnormal coagulation activity,
as well as during anticoagulant therapy, and studied
the sensitivity to lowered concentrations of coagula-
tion factors. Finally, the possibility of reducing the
volumes of sample and reagent was explored.
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Materials and Methods
Samples
Venous blood samples, received by the laboratory for monitor-
ing anticoagulant therapy or for screening the coagulation state,
were used for the study. We collected 280 samples for compar-
ison of the three tests. Citrated plasma was prepared by cen-
trifugation of nine volumes of freshly drawn blood with one
volume of trisodium citrate (0.109 mol/1) for 10 min (1600g)
at 25 °C. Plasma was used immediately, or stored at — 70 °C
in plastic tubes and thawed with tap water for 5 min before
use. Normal pool plasma was collected from 20 outpatients.
Two samples with a prothrombin time deviating more than
3 SD from the mean were excluded. Equal volumes of the
remaining 18 samples were mixed and stored in small aliquots
at — 70°C. The prothrombin time of this pool did not differ
significantly from the value of a pool of 50 healthy blood
donors. Other pool plasmas were mixtures of patient samples
selected after assay with the Thrombotest®.
Other materials
Plasmas deficient in factor VII (less than 2% of normal level),
or in factor II, V or IX (each less than 1% of normal level)
were obtained from Merz and Dade (Dudingen, Switzerland);
factor X-deficient plasma (less than 1% of normal level) was
from Behringwerke AG (Marburg, FRG).
Precinorm® control plasmas were obtained from Boehringer
Mannheim GmbH (Mannheim, FRG) and CTS Control plas-
mas from Behringwerke AG (Marburg, FRG).
Photometr ic reagents
We used two recently developed reagents for the photometric
determination of prothrombin time. The Chromoquick® re-
agent (Behringwerke AG, Marburg, FRG) consists of throm-
boplastin from human placenta, the chromogenic substrate for
thrombin, tosylglycyl-L-prolyl-L-arginyl-5-amino-2-nitroben-
zoic acid isopropylamide chloride 50 μπιοΐ/ΐ, sodium chloride
50 mmol/1, calcium chloride 5 mmol/1, HEPES buffer 25 mmol/1
and the heparin antagonist hexadimethrin bromide (Poly-
brene®). The Thromboquant® prothrombin time reagent (Boeh-
ringer Mannheim GmbH, Mannheim, FRG) consists of calcium
thromboplastin from rabbit brain, the chromogenic substrate
for thrombin, tosyl-glycyl-L-prolyl-L-arginyl-p-nitroanilide
(ChromozynV* TH) 50 μπιοΐ/ΐ, calcium chloride 6 mmol/I and
Tris/HCl buffer 100 mmol/1, pH 8.1.
Principle of the photometr ic tests
During a lag phase the extrinsic coagulation system is activated
by thromboplastin in the presence of calcium ions, resulting in
the generation of thrombin. A chromogenic substrate, which is
specific for thrombin, is then hydrolysed with liberation of a
chromophore, of which the absorbance is measured at 405 nm.
The reaction product is 5-amino-2-nitrobenzoic acid isopro-
pylamide in the Chromoquick test and /Miitroanilide in the
Thromboquant lest. The prothrombin time corresponds to the
time elapsed from the start of the reaction until an increase of
0.1 absorbance has been obtained. The fibrinogen concentration
can roughly be estimated in the same system by calculating the
increase of the absorbance caused by the formation of fibrin,
which starts shortly after the hydrolysis of the chromogenic
substrate (13, 15).
Performance of the photometric tests
A Cobas Bio® centrifugal analyser (Hoffmann-La Roche, Basel,
Switzerland) was coupled to an Epson HX-20 calculator in the
Thromboquant method and to a Hewlett Packard HP-85 cal-
culator in the Chromoquick method. The test conditions are
given in table 1. Programs for calculation of the results were
provided by the reagent manufacturers. The start of the reaction
was fixed at 5.5 s before the time of first reading in the Chromo-
quick program and at 10 s in the Thromboquant program. The
end of the prothrombin time was assessed by interpolation of
the data taken every 10 s. The reagent tube«'sfnd cuvette of the
Cobas Bio® were thermostatically controlled at 37 °C. Between
runs the reagent tube was closed to limit evaporation, because
an increase in the calcium and buffer concentrations increases
the reaction time (17).
Tab. 1 . Instrument settings of the
Parameter Listing
1 Units
2 Calculation factor
3 Standard 1 cone.
4 Standard 2 cone.
5 Standard 3 cone.
6 Limit
7 Temperature ( °C)
8 Type of analysis
9 Wavelength (nm)
10 Sample volume (μί)
11 Diluent volume (μί)
12 Reagent volume (μί)
13 Incubation time (s)
14 Start-reagent volume (μί)
15 Time of first reading (s)
16 Time interval (s)
17 Number of readings
18 Blanking mode
19 Printout mode
Cobas Bio®
Chromo-
quick®
own
1000
0
0
0
0
37.0
2
405
20
5
200
0
0
0.5
10
16
1
3
Thrombo-
quant®
own
1000
0
0
0
0
37.0
2
405
12
5
180
0
0
10.0
10
16
1
3
Coagulometric assay of prothrombin time
The coagulometric prothrombin time assay according to Ο wren
(3, 18) was performed in whole blood with Thrombotest®
reagent (Nycomed AS, Oslo, Norway) on a Lode® coagulo-
meter (Lode Instruments, Groningen, The Netherlands). The
reagent contains ox-brain thromboplastin, cephalin and calcium
chloride 3.2 mmol/1, and excess factor V and fibrinogen.
Calculations
In the coagulometric as well as in the photometric methods the
prothrombin ratio (R), International Normalized Ratio (INR)
and percentage Thrombotest activity were provided by the
calculators. R is the quotient of the prothrombin time measured
in a patient sample and in normal pool plasma. INR was
calculated from R with the relation INR = RISI using the
International Sensitivity Index (ISI) stated for the reagent batch
(19). The percentage Thrombotest was calculated from the INR
with the empirical assessed relation (20, 21) INR = 0.8 + (20/
Thrombotest percentage). The relation between the Thrombo-
test percentages estimated in patient samples by different meth-
ods was calculated by the orthogonal regression analysis of
Deming (22, 23).
Determination of the stability of photometric re-
agents
Reagents were kept at 4 °C, 25 °C and 37 °C and the percentage
Thrombotest was determined in freshly thawed CTS Control
plasmas after 1, 2, 4 and 6 h storage, then*daily during three
days storage at 25 °C and six days storage at 4°C. Linear
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regression and standard error of estimate (SEE) were calculated
for the dependence of the percentage Thrombotest on the stor-
age time. The limit of stability was defined as the ratio 2 SEE/b,
in which b is the regression constant of the relation between
the percentage Thrombotest and the storage time.
Determinat ion of the sens i t iv i ty of p ro th rombin
time reagents to the concentrat ion of single factors
Plasmas with concentrations of single factors varying from 5%
to 100% were prepared by mixing one volume of normal pool
plasma, which was undiluted or prediluted with Owren's buffer
(18), with one volume Owren's buffer and two volumes plasma
deficient in a single factor.
Results
In figure 1 the development of the absorbance in both
photometric tests is demonstrated for plasmas with
percentage Thrombotest activities varying from 8%
to 55%. In the Chromoquick test the lag time is
shorter, the reaction develops faster and the difference
of the absorbance is greater than in the Thrombo-
quant test. This is in agreement with the finding of
shorter prothrombin time values in the Chromoquick
test. The prothrombin time, determined in quadru-
plicate in normal pool plasma, was 21.2s in the
Chromoquick test and 34.5 s in the Thromboquant
test, while it amounted to 36.7 s in the Thrombotest.
Reproducibility
The reproducibility of both photometric tests was
assessed by multiple determinations in pooled plasma
and in lyophilized control plasmas with normal as
well as variously prolonged prothrombin time values.
Freshly thawed samples were determined on different
days for the examination of the between-run varia-
bility. The intra- and inter-assay CV for the prothrom-
bin time were 0.3 — 1.1 % and 0.8 - 2.0%, respectively,
in the Chromoquick tests and 0.8 — 1.2%, and 1.5 —
4.2%, respectively, in the Thromboquant tests. The
intra- and inter-assay CV for the percentage Throm-
botest activity were 0.6-4.7% and 2.1-11.5%, re-
spectively, in the Chromoquick test and 1.5 — 4.8%
and 5.5 — 8.3%, respectively, in the Thromboquant
test. Samples with Thrombotest activity in the ther-
apeutic range of oral anticoagulation exhibited much
better precision than samples with normal Throm-
botest activity (tab. 2 and 3).
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Fig. 1. Recorder profiles of photometric prothrombin time tests
in plasmas with various Thrombotest coagulation activ-
ities: A: 6%; B: 13%; C: 22%; D: 41% and E: 55%.
a) Thromboquant®
b) Chromoquick®
Stability of reagents
The stability of the photometric reagents was assessed
with CTS Control plasmas, containing normal and
subnormal activities, as well as a therapeutic level for
anticoagulant therapy. Stability limits of the reagents
during storage at 4 °C, 25 °C and 37 °C are given in
table 4. Our findings corresponded with the values
stated by the manufacturers for storage at 4 °C. How-
ever, we found much lower stability at higher tem-
peratures. On average, the relative decrease of the
percentage Thrombotest was 14% at the stability
limits.
We also assayed the relative decline of the measured
percentage Thrombotest activity in eight patient plas-
mas with various Thrombotest activities, while keep-
ing the reagents at 37 °C in an uncovered container
of the Cobas Bio® analyser for 1 h, 2 h and 4 h,
respectively. Under these conditions, the mean relative
decline of the Thrombotest percentages was 5%, 12%
and 30%, respectively, using the Chromoquick test.
With the Thromboquant test the mean relative decline
was 6%, 16% and 42%, respectively.
Comparison of methods
Results of the Chromoquick and Thromboquant as-
says in plasmas were compared with Thrombotest0*
results in 280 samples of whole blood from patients
undergoing oral anticoagulant therapy or screening
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Tab. 2. Intra- und inter-assay variation of the Thromboquant® test. Freshly thawed samples were estimated twenty times within
one run, as well as on twenty different days.
Plasma
Pool plasma
Pool plasma
Pool plasma
Precichrom® normal
Precichrom® abnormal
Prothrombin time
(s)
intra-assay
mean CV (%)
42.0 1.2
49.6 1.2
80.2 1.0
37.2 0.8
103.0 1.0
inter-assay
mean
42.3
46.4
79.8
37.2
96.8
CV (%)
2.8
2.8
2.6
1.5
4.2
Thrombotest
coagulation activity (%)
intra-assay inter-assay
mean CF (%) meam
42.2 4.8 42.0
26.1 3.5 26.5
9.7 1.5 10.1
66.4 3.0 66.4
6.5 2.2 7.2
CV (%)
8.3
6.8
5.5
7.1
6.8
Tab. 3. Intra- and inter-assay variation of the Chromoquick® test. Freshly thawed samples were estimated ten times within one
run, as well as on ten different days.
Plasma Prothrombin
(s)
time
intra-assay
Pool plasma
Pool plasma
Pool plasma
CTS Control
CTS Control
CTS Control
plasma
plasma
plasma
N
PI
P2
mean
21.9
28.7
39.6
20.6
25.2
57.8
Thrombotest
coagulation activity (%)
inter-assay
CV (%) mean
1.
0.
0.
0.
0.
0.
.1
,7
.3
,7
,5
,8
21.8
29.7
39.8
20.7
24.9
57.5
CV (%)
1.2
0.9
1.4
2.0
0.8
1.9
intra-assay
mean
75.0
28.6
15.8
96.4
42.4
8.5
inter-assay
CV (%) mean
4.7
1.6
0.6
3.7
1.5
1.4
75.3
28.5
15.7
98.7
46.4
8.6
CV (%)
5.0
2.1
2.7
11.5
2.5
4.0
Tab. 4. Stability of the photometric prothrombin time reagents stored at several temperatures. Coagulation activity was determined
in CTS control plasmas with normal (N) and subnormal (PI) activity as well as a therapeutic level for anticoagulant
treatment (P2). ΔΑ: relative decline of thrombotest coagulation activity at the estimated stability limit (%); L: estimated
stability limit (days or hours); LR: stability limit stated by the manufacturer.
Storage Plasma
temperature
4°C
25 °C
37 °C
N
PI
P2
N
PI
P2
N
PI
P2
Chromoquick®
ΔΑ
23.9%
16.2%
10.7%
20.3%
22.9%
6.7%
14.2%
9.6%
5.5%
L L LR
6.6 d
8.1 d 7d 7d
6.0 d
31 h
39 h 31h 48 h
22h
2.2h
1.7h 2h 8h
2.4h
Thromboquant®
ΔΑ
12.1%
14.9%
5.7%
19.0%
13.8%
6.1%
20.3%
6.2%
4.7%
L L
1.8 d
4.8 d 5 d
7.2 d
11.6h
9.7h 10h
7.7h
4.4h
1.6h 4h
4.6h
LR
5d
24h
8h
for their coagulation state (fig. 2 and tab. 5). The
correlation between the photometric tests and Throm-
botest® was better in the therapeutic range than in
subnormal or normal ranges. The Chromoquick test
correlated better with the Thrombotest® than the
Thromboquant in all activity ranges. Thfomboquant
correlated rather poorly with the Thrombotest® in
subnormal and normal ranges. The regression con-
stant of the relation between Chromoquick and
Thrombotest® results amounted to 1.58 for the whole
activity range and increased from 1.30 in the thera-
peutic range to 3.27 in the normal range. Unlike the
computerized program for Thromboquant, the stand-
ard program for Chromoquck included 5 s mixing of
sample and reagent in the prothrombin time. In an-
other collection of 152 samples, we therefore com-
pared the Thrombotest® results with Chromoquick
results, using a modified computer program, in which
the start of the prothrombin time was fixed at 0.5 s
before the first reading, instead of 5.5 s. This im-
proved the regression constant considerably. The
regression constant of the relation between Throm-
J. Clin. Chem. Clin. Biochern. / Vol. 26, 1988 / No. 12
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Fig. 2. Comparison of Thrombotest coagulation activity assayed by photometric and coagulometric methods.
A: Thromboquant® and Thrombotest®;
B: Chromoquick® and Thrombotest®;
C: Chromoquick® and Thromboquant®.
Tab. 5. Correlation between photometric and coagulometric methods. Correlation coefficient (r) and orthogonal regression of
the relation y = a 4- b · χ for various ranges of Thrombotest coagulation activity. CQm: Chromoquick^ results after
modification of the Behring computer program (see text), CQ: Chromoquick®, TQ: Thromboquant®.
Methods Overall range Thrombotest: 3-20% Thrombotest: 20-50% Thrombotest: 50-100%
n a a a
CQ/Thrombotest 278
CQm/Thrombotest 152
TQ/Thrombotest 280
CQ/TQ 277
0.94
0.92
0.86
0.92
-5.8
0.71
-7.5
3.8
1.58
1.06
1.37
1.12
181
120
183
175
0.91
0.92
0.78
0.76
-0.3 1.30
-0.01 0.99
-2.0 1.17
-5.2 1.84
54 0.81
26 0.87
54 0.42
72 0.66
-27.2 2.19
9.6 0.63
-66 3.63
43 0.75
6
43 0.67
30 0.73
-133
-216
8.8
3.27
4.19
1.00
boquant and Thrombotest® results varied greatly in
the three distinct activity ranges. In the normal range
the results of the Thromboquant test were much
higher than in the Thrombotest®. In two patients the
percentage Thrombotest activity was estimated by all
three methods during three weeks, in which oral an-
ticoagulant therapy was adjusted. As shown in figure
3 the pattern of results with Chromoquick, and to a
lesser extent with Thromboquant, reflected the alter-
ations of the Thrombotest® results.
Sensitivity to the concentration of coagula-
tion factors
The sensitivity of the prothrombin time to the vitamin
K-dependent clotting factors is different and charac-
teristic for each type of thromboplastin. We therefore
examined in vitro the relation between the prothrom-
bin ratio and the concentration of the single factors
II, VII9IX and X. The dependence of the prothrombin
ratio on factor V was only measured with Chromo-
quick and Thromboquant reagents, because the
Thrombotest® reagent is supplied with this factor.
The log of the prothrombin ratio is linearly related
to the log of single factor concentrations (fig. 4).
With respect to the extrinsic coagulation factors, both
photometric tests showed the highest sensitivity to
factor V, intermediate sensitivity to factor II and X
and the least, but still good sensitivity to factor VII.
Fifty percent reduction of factor II, VII or X gave
prothrombin-ratio values between 1.2 and 1.3 in all
three methods. For factor V, the prothrombin ratio
lay between 1.3 and 1.4 with Thromboquant and
Chromoquick reagents. These values are well above
the normal range of 0.89—1.11 for Thromboquant
(12) and 0.87-1.12 for Chromoquick (24). The sen-
sitivity to the intrinsic factor IX was very low in both
tests. The Thrombotest® was nearly equally sensitive
to factor II, VII and X and nearly insensitive to factor
IX. The three reagents showed approximately equal
sensitivity to factor II and X, while the Thrombotest^
was more sensitive to factor VII than both photo-
metric tests.
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Fig. 3. Thrombotest coagulation activity assayed by photometric and coagulometric methods in two patients during adjustment
of oral anticoagulant treatment.
o: Thromboquant®; D: Chromoquick®; x: Thrombotest®
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Fig. 4. Relation between the log of single factor concentrations
and the log of prothrombin ratio assayed with Chromo-
quick^, Thromboquant^ and Thrombotest® reagents
for factor II (D), factor V (o), factor VII (D), factor IX
(x) and factor X (o).
Reduction of the reagent volume
The effect of reduction of sample and reagent volume
on the results was studied in the interests of economy.
Twenty samples with a Thrombotest activity varying
from 4% to 90% were assayed with Chromoquick
reagent in sample volumes ranging from 3 μΐ to 20 μΐ,
all with a Yio sample/reagent ratio. A very high cor-
relation with results in 20 μΐ samples was found for
10 μΐ and higher sample volumes, while the correlation
decreased for 5 μΐ and 3 μΐ sample volumes (tab. 6).
Pool plasmas and control plasmas with various
Thrombotest activities were estimated 10 times with
Chromoquick reagent in 5 μΐ and 10 μΐ samples re-
spectively (tab. 7). The intra-assay CV ranged from
0.4% for low activities to 5.3% for high activities
Tab. 6. Correlation of results determined in various sample/
reagent volumes with results in 20 μΙ/200 μΐ sample/
reagent volume (sample dilution 11.25).
Sample/reagent
volume (μΐ)
15/150
12/120
10/100
5/50
3/30
Sample dilution
11.33
11.42
11.50
12.00
12.67
r
0.997
0.995
0.998
0.967
0.748
Tab. 7. Intra-assay variation of the Chromoquick® test in re-
lation to sample/reagent volumes (μΐ). Mean Throm-
botest coagulation activity (%) of pool plasmas and
control plasmas, each determined 10 times, and the
resulting CV (%). In both series different pool plasmas
were employed.
Sample/reagent
volume (μΐ)
Pool plasma
Pool plasma
Pool plasma
Pool plasma
Precichrom®
normal
Precichrorn®
abnormal
10 μΙ/100 μΐ
mean CV (%)
75.5 4.0
57.1 4.6
32.6 1.1
12.9 0.8
99.8 5.3
10.0 0.4
5 μ!/50μ!
mean CV (%)
76.9 7.0
64.5 5.1
48.6 · 3.9
99.7 8.3
7.2 2.1
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(mean 2.7%), using 10 μΐ samples, which corresponds
with the precision for 20 μΐ sample volume (tab. 3).
On the other hand, the CV ranged from 2.1% to
8.3% (mean 5.3%) for 5 μΐ samples. Both findings
indicate that 10 μΙ/100 μΐ sample/reagent is the small-
est volume configuration, which yields results com-
parable to the 20 μΙ/200 μΐ protocol.
Discussion
We wished to evaluate the possibility of replacing the
traditional Thrombotest® clotting method by an auto-
mated chromogenic substrate test, in order to reduce
the workload of prothrombin time tests, which are
performed mostly for the control of oral anticoagu-
lant therapy. In addition to using INR units, we
therefore also expressed the results of the chromogenic
tests in percentage Thrombotest coagulation activity,
which is customary in our hospital, in order to avoid
change of the therapeutic reference values.
Both assays of prothrombin time using chromogenic
substrates can be easily automated on a Cobas Βίο(φ
analyser, provided arrangements are made to main-
tain the reagent temperature on 37 °C. Keeping the
reagent longer than two hours on 37 °C is not advis-
able, owing to the limited stability of both reagents
at that temperature. Thus, for stat tests the reagent
should be maintained at 25 °C within one working
day or at 4 °C for longer periods.
Chromogenic substrate tests have several advantages
over coagulometric tests. Because the thrombin activ-
ity is estimated by photometric measurement of the
reaction product, these assays can be automated more
easily on common clinical-chemistry analysers. Sec-
ondly, in automated photometric prothrombin time
tests, smaller sample volumes are needed than in coa-
gulometric tests. We found that reduction of the sam-
ple volume on a Cobas Bio® analyser to 10 μΐ did not
change the precision of the Chromoquick test or the
correlation with the results of the test performed with
20 μΐ sample volume. Also in the Thromboquant test
only 12 μΐ of plasma are employed, whereas the
Thrombotest® takes 50 μΐ of whole blood in the macro
Lode device.
Chromogenic prothrombin time assays are not sen-
sitive to abnormalities in the concentration or nature
of fibrinogen, which is the substrate in coagulometric
methods (12, 24, 25). Moreover, interference with the
conversion of fibrinogen to fibrin by fibrin split prod-
ucts, which occur in disseminated intravascular co-
agulation and thrombolytic therapy, can prolong the
clotting time considerably, although the generation of
thrombin is not affected. In such situations, the pho-
tometric assay, which uses a constant concentration
of an artificial substrate, is little influenced (24).
Therefore, chromogenic assays are more useful for
the evaluation of coagulation pathways independent
of the conversion of fibrinogen to fibrin. Plasma sam-
ples containing bilirubin concentrations up to 300
μηιοΐ/l, haemoglobin concentrations up to 5 g/1 or
chylomicrons produce no interference with the pho-
tometric prothrombin time assay (24).
In photometric assays a better precision is attained
than in coagulometric assays (12, 26, 27). In our study
the inter-assay CV of the prothrombin time amounted
to 2.0% or less in the Chromoquick test and 4.2% or
less in the Thromboquant test. Values for the inter-
assay CV of the prothrombin time not exceeding 3.4%
(24) and 2.6% (26) have been reported for the
Chromoquick test and not higher than 2.0% (12, 25)
for the Thromboquant test. These, as well as our
results, indicate that both photometric prothrombin
time assays possess good between-assay reproducibil-
ity. The Chromoquick reagent gave a somewhat better
precision at all coagulation activity levels than the
Thromboquant reagent. With an automated chrom-
ogenic substrate method, many tests per hour can be
performed by one technician. Assuming that one as-
say takes 4 min by the clotting method, 90 tests per
hour can be done on a 6-channel Lode® coagulometer.
With a Cobas Bio® analyser, it takes 6 min for a run
of 29 tests and one technician can perform 290 tests
per hour. A disadvantage of photometric tests is that
samples must be centrifugated, while the Thrombo-
test® can be done in whole blood, but the result can
be affected by an aberrant haematocrit, and by the
presence of bilirubinaemia, lipidaemia and haemo-
lysis.
Values of the Thrombotest activity assayed with
Chromoquick reagent correlated well in various ac-
tivity ranges with the Thrombotest activity assayed
by the clotting method. However, when the prothrom-
bin time was estimated with the standard calculation
program, orthogonal regression demonstrated a de-
viation of the percentage Thrombotest results by both
methods. With a modified calculation program, in
which the mixing time was excluded from the pro-
thrombin time, good conformity between Thrombo-
test® and Chromoquick results was attained, partic-
ularly in the therapeutic activity range. Correlation
as well as orthogonal regression indicated notable
deviations between the percentage Thrombotest re-
sults by the Thromboquant and Thrombotest® meth-
ods outside the therapeutic region.
A possible explanation for this finding could be that
the ISI value used for the Thromboquant reagent was
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not sufficiently accurate, because good correlation
between values for prothrombin time by the Throm-
boquant and coagulometric methods has been re-
ported (12, 13). Otherwise, unsatisfactory agreement
between INK results of two different prothrombin
time assays has been mentioned recently, suggesting
that the introduction of INR units may not have
solved the comparability problems for all types of
thromboplastins (28). In that study, results with
Thrombotest® reagent were also compared with the
results of an automated coagulometric test based on
thromboplastin from rabbit brain. Our results con-
firm that both photometric tests are well suited for
monitoring oral anticoagulant therapy, as previously
described for Thromboquant (11) and Chromoquick
(24, 26). Both reagents can be applied to plasma
samples from patients under heparin therapy during
conversion to oral anticoagulation. In vitro experi-
ments indicated that Thromboquant is nearly insen-
sitive to heparin up to a concentration of at least 0.8
USP/ml plasma (11) and Chromoquick up to 1.0
USP/ml, due to the presence of added heparin antag-
onist (15, 27).
The sensitivity of both reagents to the individual
clotting factors II, V, VII and X isf good, as was
demonstrated by in vitro experiments. Both photo*
metric tests showed comparable sensitivities, while the
Thrombotest® reagent was more sensitive to factor
VII. The sensitivity of the photometric reagents is
suitable for these tests of overall clotting ability, as
well as the measurement of individual clotting factors
in one-stage assays, which require much less factor-
deficient plasma than a clotting method. It should be
noted that for both chromogenic assays the highest
sensitivity was found against factor V deficiency. This
could be a disadvantage when monitoring oral anti-
coagulation, since acquired factor V deficiencies are
relatively frequent.
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